DSIP Peptide FAQ: Frequently Asked Questions

DSIP (Delta Sleep-Inducing Peptide, also called emideltide) is a naturally occurring nonapeptide — nine amino acids: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu — isolated from the cerebral venous blood of sleeping rabbits by Monnier and Schoenenberger between 1963 and 1977. It is found endogenously in humans, primarily in a phosphorylated form (DSIP-P), and has been studied for sleep regulation, stress modulation, and GH secretion across four decades of research.^[23][24]

Research has documented sleep quality improvement in four controlled human insomnia trials,^[1][3][4][5] pain reduction in a seven-patient pilot study,^[18] high response rates in opiate and alcohol withdrawal cohorts (97% and 87% respectively, n=107),^[16] GH secretion stimulation in rodent models,^[7] and neuroprotective and lifespan effects in mouse aging studies.^[25] Human data for non-sleep benefits is limited to small, often single-group trials.

Four controlled human studies document consistent improvement in sleep in chronic insomniacs. Bes et al. (1992) found higher sleep efficiency and shorter sleep latency vs. placebo in 16 patients at 25 nmol/kg IV.^[1] Notably, a daytime dose in one study improved the following night's sleep rather than acting as a direct sedative^[2] — consistent with a circadian entrainment mechanism.

Human trial literature reports few adverse effects. The 107-patient withdrawal cohort found good tolerance with occasional headache as the only notable side effect.^[16] The seven-night insomnia trial found no adverse events and daytime performance improvement.^[3] Robust long-term human safety data does not exist; no large controlled trial has been completed.

In the acute IV insomnia study, sleep benefit appeared beginning in the second hour post-injection.^[2] In the seven-night trial, improvement was observed from the first treatment night.^[3] Daytime administration may improve the following night's sleep rather than acting acutely, based on Schneider-Helmert (1981)^[2] — consistent with a circadian-entraining mechanism.

The strongest human evidence is the Bes et al. (1992) double-blind study (PMID 1299794, n=16) showing statistically significant improvement in sleep efficiency vs. placebo.^[1] Three additional controlled insomnia studies report consistent directional benefit.^[2][3][4] The evidence base is small and concentrated in one research era; no Phase III trial has been completed.

Research applications include sleep disorders (primary indication, four human trials), opioid and alcohol withdrawal (107-patient cohort),^[15][16] chronic pain management (7-patient pilot),^[18] narcolepsy (single case study),^[17] GH secretion mechanistic studies,^[7] intranasal neuroprotection in stroke models,^[28] and aging/anti-tumor studies in mice.^[25]

Published human clinical trials used intravenous administration exclusively. Animal studies have used subcutaneous, intracerebroventricular, and intranasal routes.^[13][25][28] Intranasal delivery is under investigation for improved CNS bioavailability, supported by pharmacokinetic data showing lipophilicity and plasma concentration predict CSF penetration.^[12] No human data compares routes directly.

Yes, in both animal and human data. Subcutaneous DSIP in cats increased slow-wave sleep without suppressing REM.^[13] EEG analysis in rats showed selective amplification of delta/theta activity up to eleven hours post-administration without disrupting REM architecture.^[14] The acute human study (Schneider-Helmert 1981) found a modest increase in REM alongside sleep improvement.^[2]

Yes — confirmed in vascularly perfused guinea pig brain via a high-affinity saturable transport mechanism, with competitive inhibition by L-tryptophan (DSIP's N-terminal residue).^[10] CSF penetration of DSIP analogs in dogs correlated strongly with plasma concentration, half-life, and lipophilicity (r=0.813, p<0.00005).^[12] A 2024 study showed an engineered BBB-crossing DSIP fusion protein outperformed native DSIP in insomniac mice.^[26]

Animal and in vitro studies suggested DSIP inhibits ACTH-stimulated cortisol release. The controlled human IV study (Spath-Schwalbe et al. 1995, PMID 7777652) found no effect on CRH-stimulated ACTH or cortisol responses vs. placebo.^[9] HPA axis suppression has not been confirmed in a controlled human study at the doses used in insomnia trials.

In rat models, ICV injection of 5 mcg DSIP elevated plasma GH within 30 minutes via a hypothalamic dopaminergic pathway blocked by pimozide.^[7] ICV DSIP antiserum blocked sleep-related GH surges in sleep-deprived rats.^[6] In healthy women, IV DSIP infusion did not change spontaneous or arginine-stimulated GH secretion^[8] — suggesting GH-releasing effects may be more prominent in rodent models.

Free DSIP plasma half-life is 2-4 minutes across species (2.0 min in rat, 2.9 min in monkey, 4.0 min in dog).^[11] Despite this, in-vivo effects last hours to days. Carrier protein binding and the downstream neuroendocrine cascades DSIP initiates — GH pulse, melatonin release — are proposed explanations. Endogenous DSIP-P (phosphorylated form) resists aminopeptidase degradation and is more potent.^[23]

No physical dependence has been reported in published human trials. DSIP does not appear to act on GABA-A receptors — the primary mechanism for benzodiazepine dependence. No withdrawal syndrome has been described in any published study following cessation. Long-term human safety data is lacking.

No. DSIP is a naturally occurring neuropeptide, not a sedative or hypnotic. It appears to modulate sleep architecture — promoting slow-wave delta sleep — via circadian and neuroendocrine pathways rather than directly inducing sedation. A daytime dose can improve the following night's sleep,^[2] which is inconsistent with a direct sedative mechanism.

Melatonin shifts the circadian phase (sleep-onset window) via MT1/MT2 receptor binding. DSIP is not a melatonin receptor agonist and does not primarily phase-shift the circadian clock. Instead it amplifies slow-wave sleep architecture and stimulates pineal melatonin synthesis via a distinct non-adrenergic pathway.^[19] Endogenous DSIP peaks in the afternoon (15:00), not at dusk like melatonin.^[21]

Yes, in animal studies: GH secretion via a dopaminergic hypothalamic pathway,^[7] LH release via hypothalamic LHRH secretion (FSH not affected),^[20] and pineal melatonin, serotonin, and 5-methoxytryptophol synthesis.^[19] Human data shows no effect on GH in healthy women^[8] and no effect on cortisol in healthy men.^[9] Hormonal effects in humans may differ from rodent models.

Animal data supports this claim. Monthly DSIP preparation (Deltaran) in SHR mice extended maximum lifespan by 24.1%, reduced spontaneous tumor incidence 2.6-fold, and decreased chromosome aberrations by 22.6%.^[25] Intranasal DSIP significantly improved motor recovery after focal stroke in rats.^[28] Human neuroprotection data does not exist.

Yes — two studies from Dick et al. Dick et al. (1983) reported beneficial response in 48/49 evaluable patients in a combined opiate/alcohol withdrawal cohort (n=67).^[15] Dick et al. (1984) extended this to 107 inpatients and found 97% response in opiate withdrawal and 87% in alcohol withdrawal, with rapid onset of somatic symptom relief and good tolerance.^[16]

A single case study (Schneider-Helmert 1984, PMID 6548968) reported reduced daytime sleep attacks, increased daytime alertness, enhanced REM, and compressed sleep period in a 35-year-old narcoleptic male.^[17] This is one patient — no controlled narcolepsy trial has been published. The investigator attributed effects to circadian and ultradian rhythm accentuation.

DSIP produces maximal effect at an intermediate dose (approximately 1 mcg in some assays) with diminishing returns at both lower and higher doses.^[23] This non-linear dose-response — termed parabolic or U-shaped — means dose selection in research protocols significantly affects observed outcomes. Very low and very high doses produce less pronounced effects than the optimal intermediate range.

All major controlled human trials enrolled patients with clinically diagnosed chronic insomnia. Bes et al. (1992) specified chronic insomnia; Schneider-Helmert (1986) documented this in a middle-aged and elderly cohort.^[1][5] Whether effects generalise to situational or transient insomnia has not been rigorously studied in the published literature.

Plasma DSIP levels in humans peak at approximately 15:00 and reach a nadir at approximately 01:00, with a circadian correlation to body temperature (r²=0.66, p<0.0001) rather than sleep onset (Friedman et al. 1994, PMID 8175965).^[21] Exogenous DSIP may reinforce endogenous circadian oscillations — accounting for the finding that daytime dosing improves the subsequent night's sleep.^[2]

No rebound insomnia has been reported in any published trial. The seven-night insomnia study found sleep improvements persisting after the treatment course ended.^[3] The ten-injection study reported benefit at three-to-seven-month follow-up.^[4] The delayed sleep phase case reported sustained benefit post-treatment with no resumption of benzodiazepine use.^[22] This is consistent with a non-GABA-A mechanism and the circadian-reinforcement model.

Controlled human efficacy data exists only for IV administration. Subcutaneous DSIP is documented in animal models (cat EEG study at 120 nmol/kg SC;^[13] mouse aging study at ~100 mcg/kg SC monthly^[25]). Intranasal DSIP was used in a rat stroke recovery study^[28] and supported by pharmacokinetic data showing lipophilicity predicts CNS penetration.^[12] No human comparative study across routes has been published.

Despite four decades of research, a dedicated DSIP receptor and a DSIP precursor gene remain unidentified. Kovalzon and Strekalova's 2006 review (PMID 16539679) characterized this as "a still unresolved riddle."^[24] The authors propose DSIP may act through multiple low-affinity receptor interactions, or that a structurally related endogenous molecule — not native DSIP — is the primary active entity. The pharmacological record is robust; the molecular mechanism remains open.

At the functional level, delta sleep-inducing peptide promotes slow-wave (delta) sleep, modulates the stress response, supports GH secretion in rodent models, stimulates pineal melatonin synthesis,^[19] and has been studied for pain modulation^[18] and neuroprotection^[25][28] in animal models. Sleep architecture modulation is the best-documented effect in controlled human trials.^[1][2][3][4]

DSIP is the peptide most specifically named for sleep induction, with the only controlled human trials measuring sleep architecture as a primary endpoint. Selank and Semax address sleep-adjacent stress and anxiety pathways. Kisspeptin and growth hormone-releasing peptides couple to the GH-sleep axis but their primary research context is neuroendocrine rather than primary sleep architecture. No direct comparative trial between these compounds for sleep outcomes has been published.

Published research protocols range from three to ten consecutive daily injections for insomnia applications^[1][3][4] to every-48-72-hour follow-up dosing in the pain protocol.^[18] Monthly five-day courses were used in the mouse aging study.^[25] No optimal frequency has been established for any indication, and the U-shaped dose-response complicates generalisation across protocols.^[23]

In controlled human insomnia trials, DSIP was administered IV before bedtime at 25 nmol/kg.^[1] One study showed a daytime dose improved the following night's sleep,^[2] consistent with circadian entrainment rather than direct sedation. The optimal dose, frequency, and timing have not been established in a systematic dose-finding study; existing data is from protocols designed for specific therapeutic applications rather than dose optimization.